Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Oryn Therapeutics

Oryn Therapeutics?uq=2zON1W4M
2013 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Grant LATEST DEAL TYPE
$5.3M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of synthetic therapeutic cyclic peptide technologies designed to induce the remission of rheumatoid arthritis and treat drug-resistant infections. The company's Orynotides employ naturally-occuring endogenous theta-defensins, enabling patients to receive retro-evolutionary therapies for inflammatory, autoimmune and infectious diseases.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Primary Office
  • 3333 Vaca Valley Parkway
  • Suite 400
  • Vacaville, CA 95688
  • United States

+1 (530) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Oryn Therapeutics’s full profile, request a free trial.

Oryn Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 17-May-2016 $5.3M 000 Completed Startup
2. Angel (individual) 02-Sep-2015 000 000 Completed Startup
1. Grant 01-Jan-2015 $1.5M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Oryn Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
National Institutes of Health Government 000 0000 000000 0
Mark Armenante Angel (individual) Minority 000 0000 000000 0
Young Sohn Angel (individual) Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0

Oryn Therapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Richard Selsted Ph.D Chief Operating Officer & Board Member
Michael Selsted Ph.D Co-Founder & Chief Scientific Officer
Percio Gulko MD Chief Medical Officer
Robert Erwin Chairman

Oryn Therapeutics Board Members (4)

Name Representing Role Since Contact
Info
Mark Armenante Self Board Member 000 0000
Richard Selsted Ph.D Oryn Therapeutics Chief Operating Officer & Board Member 000 0000
Robert Erwin Self Chairman 000 0000
Young Sohn Self Board Member 000 0000